Anja Klingeberg1, Ines Noll, Niklas Willrich, Marcel Feig, Dagmar Emrich, Edith Zill, Annegret Krenz-Weinreich, Wiltrud Kalka-Moll, Klaus Oberdorfer, Guido Schmiemann, Tim Eckmanns. 1. Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany; Charité-Universitätsmedizin Berlin, Germany; LADR GmbH, Medizinisches Versorgungszentrum Plön, Germany; MVZ Dr. Stein und Kollegen GbR, Mönchengladbach, Germany; MVZ Labor Dr.Limbach & Kollegen GbR, Heidelberg, Germany; Medizinisches Versorgungszentrum, Labor 28 GmbH, Berlin, Germany; Department for Health Services Research, Institute for Public Health and Nursing Science, Bremen, Germany.
Abstract
BACKGROUND: Routine urine culture testing is not recommended for uncomplicated urinary tract infections (UTIs). As a result, the antibiotic resistance patterns or the organisms causing UTIs are not adequately reflected in routine data. We studied the sensitivity of Escherichia coli (E. coli) to trimethoprim (TMP) and to cotrimoxazole (i.e., trimethoprim/sulfamethoxazole, TMP/SMX) in community-acquired UTI and compared the findings with the resistance data of the Antimicrobial Resistance Surveillance System (ARS). METHODS: General practitioners and internists in private practice prospectively recruited all of their adult patients with symptoms of a urinary tract infection from May 2015 to February 2016. Urine specimens from all patients were tested (including urine culture testing and antibiotic susceptibility) and infections were defined as uncomplicated or complicated UTIs. RESULTS: 1245 participants from 58 medical practices were enrolled in the study. Pathogenic organisms were found in the urine of 877 patients, of whom 74.5% had E. coli infections. Among the E.-coli-positive UTIs, 52.4% were classified as uncomplicated and 47.6% as complicated. The prevalence of E. coli that was resistant to TMP and to TMP/SMX in uncomplicated UTIs was 15.2% and 13.0%, respectively, compared to 25.3% and 24.4%, respectively, from all UTIs in ARS in 2015. Study participants who had previously taken antibiotics had the highest prevalence of E. coli resistance (30.9%), followed by those who had two or more UTIs within the past six months (28.9%). CONCLUSION: E. coli with resistance to TMP was significantly less prevalent among the study patients with uncomplicated UTIs than in the routine data of the ARS. Accordingly, TMP should still be considered as an option for the treatment of uncomplicated UTIs. TMP/SMX is considered the agent of second choice because of its side effects. Surveillance systems based on routine data do not yield a representative sample for the evaluation of the resistance situation in patients with uncomplicated UTIs.
BACKGROUND: Routine urine culture testing is not recommended for uncomplicated urinary tract infections (UTIs). As a result, the antibiotic resistance patterns or the organisms causing UTIs are not adequately reflected in routine data. We studied the sensitivity of Escherichia coli (E. coli) to trimethoprim (TMP) and to cotrimoxazole (i.e., trimethoprim/sulfamethoxazole, TMP/SMX) in community-acquired UTI and compared the findings with the resistance data of the Antimicrobial Resistance Surveillance System (ARS). METHODS: General practitioners and internists in private practice prospectively recruited all of their adult patients with symptoms of a urinary tract infection from May 2015 to February 2016. Urine specimens from all patients were tested (including urine culture testing and antibiotic susceptibility) and infections were defined as uncomplicated or complicated UTIs. RESULTS: 1245 participants from 58 medical practices were enrolled in the study. Pathogenic organisms were found in the urine of 877 patients, of whom 74.5% had E. coli infections. Among the E.-coli-positive UTIs, 52.4% were classified as uncomplicated and 47.6% as complicated. The prevalence of E. coli that was resistant to TMP and to TMP/SMX in uncomplicated UTIs was 15.2% and 13.0%, respectively, compared to 25.3% and 24.4%, respectively, from all UTIs in ARS in 2015. Study participants who had previously taken antibiotics had the highest prevalence of E. coli resistance (30.9%), followed by those who had two or more UTIs within the past six months (28.9%). CONCLUSION:E. coli with resistance to TMP was significantly less prevalent among the study patients with uncomplicated UTIs than in the routine data of the ARS. Accordingly, TMP should still be considered as an option for the treatment of uncomplicated UTIs. TMP/SMX is considered the agent of second choice because of its side effects. Surveillance systems based on routine data do not yield a representative sample for the evaluation of the resistance situation in patients with uncomplicated UTIs.
Authors: Florian M E Wagenlehner; Udo Hoyme; Martin Kaase; Reinhard Fünfstück; Kurt G Naber; Guido Schmiemann Journal: Dtsch Arztebl Int Date: 2011-06-17 Impact factor: 5.594
Authors: I Noll; B Schweickert; M Abu Sin; M Feig; H Claus; T Eckmanns Journal: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz Date: 2012-11 Impact factor: 1.513
Authors: Michael Kresken; Yvonne Pfeifer; Florian Wagenlehner; Guido Werner; Esther Wohlfarth; On Behalf Of Study Group 'Antimicrobial Resistance' Of The Paul Ehrlich Society For Infection Therapy Journal: Antibiotics (Basel) Date: 2022-05-31
Authors: Vicky Watts; Benjamin Brown; Maria Ahmed; André Charlett; Carolyn Chew-Graham; Paul Cleary; Valerie Decraene; Kirsty Dodgson; Ryan George; Susan Hopkins; Aneez Esmail; William Welfare Journal: JAC Antimicrob Resist Date: 2020-05-27